Supplementary figure: Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Biologic initiation rates in systemic-naive </b><b>psoriasis patients after first-line apremilast </b><b>versus methotrexate use</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplementary Figure </b><b>1</b><b>:</b> Time to biologic initiation during the 2-year follow-up period among patients with 2 years of follow-up</li><li><b>Supplementary Table </b><b>1</b><b>: </b>Patient demographic characteristics and prescriber specialty</li><li><b>Supplementary Table </b><b>2</b><b>:</b> Baseline comorbidities</li><li><b>Supplementary Table </b><b>3</b><b>:</b> Baseline medication use</li><li><b>Supplementary Table </b><b>4</b><b>: </b>Baseline healthcare utilization, and costs</li><li><b>Supplementary Table 5: </b>Number of index medication fills before biologic initiation during the 1-year follow-up period</li><li><b>Supplementary Table 6: </b>First biologic medication used during the 1-year follow-up period among apremilast patients who initiated biologic</li><li><b>Supplementary Table 7: </b>First biologic medication used during the 1-year follow-up period among methotrexate patients who initiated biologic</li><li><b>Supplementary Table 8:</b> Biologic initiation adjusted results</li></ul><p dir="ltr"><b>Aim:</b> To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). <b>Methods:</b> This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. <b>Outcomes:</b> Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. <b>Results:</b> APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37–0.48; p < 0.001), lower adjusted biologic initiation rate (14.4% [95% CI: 13.2–15.7%] vs 28.6% [95% CI: 26.8–30.5%]), lower risk of biologic initiation (hazard ratio: 0.45; 95% CI: 0.40–0.51; p < 0.001) compared with MTX initiators. Conclusion: Systemic-naive patients with PsO have a lower rate of biologic initiation over 1 year following APR initiation.</p>